CapsoVision Inc(CV) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.62 | Insider Own | 49.45% | Shs Outstand | 50.0M | Perf Week | -2.29% |
| Market Cap | 0.36B | Forward P/E | - | EPS next Y | 19.64% | Insider Trans | 11.87% | Shs Float | 26.9M | Perf Month | 8.07% |
| Enterprise Value | 0.36B | PEG | - | EPS next Q | -0.15 | Inst Own | 9.56% | Short Float | 8.11% | Perf Quarter | -4.74% |
| Income | -0.03B | P/S | 26.16 | EPS this Y | 45.63% | Inst Trans | 10.88% | Short Ratio | 13.31 | Perf Half Y | -8.93% |
| Sales | 0.01B | P/B | 25.95 | EPS next 5Y | 48.58% | ROA | -212.19% | Short Interest | 2.18M | Perf YTD | -36.11% |
| Book/sh | 0.26 | P/C | 40.02 | EPS past 3/5Y | -48.82% - | ROE | -335.06% | 52W High | -55.56% ($15.37) | Perf Year | 45.32% |
| Cash/sh | 0.17 | P/FCF | - | Sales past 3/5Y | 17.89% - | ROIC | -222.42% | 52W Low | 51.78% ($4.50) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | 50.88% | Volatility(W/M) | 5.16% 4.33% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 25.56 | Sales Y/Y TTM | - | Oper. Margin | -217.14% | ATR (14) | 0.32 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.44 | EPS Q/Q | -51.47% | Profit Margin | -214.74% | RSI (14) | 53.99 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.35 | Sales Q/Q | 9.89% | SMA20 | 1.63% ($6.72) | Beta | -2.46 | Target Price | $9.67 |
| Payout | - | Debt/Eq | 0.05 | Earnings | 2026/11/12 | SMA50 | 6.32% ($6.42) | Rel Volume | 0.53 | Prev Close | $6.94 |
| Employees | 99 | LT Debt/Eq | 0.02 | EPS/Sales Surpr. | -15.38% -4.46% | SMA200 | 7.51% ($6.35) | Avg Volume(3M) | 0.16M | Price | $6.83 |
| IPO | 2025/7/2 | Option/Short | No/Yes | Trades | 1141 | Volume | 86,781 | Change | -1.59% |
💊 This company specializes in medical devices, specifically capsule endoscopy cameras that can be swallowed to image the small intestine and other parts of the digestive tract. Headquartered in the US, it is a small-cap medical device company that has carved out a differentiated position in the capsule endoscopy field with its 360-degree panoramic imaging technology.
Over the past 1 year, on the lower side
56% below its 1-year high.
Traded less than usual. That is 53% of its average volume.
Next earnings report: November 12
12 days to go.
CV has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +45.6% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $2,616. Peers typically go for $326.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 9.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
IWC iShares Micro-Cap ETF <0.01% 
IWO iShares Russell 2000 Growth ETF <0.01% 
HONG Leverage Shares 2X Long HON Daily ETF <0.01% 
VTWG Vanguard Russell 2000 Growth Index ETF <0.01% 
VTWO Vanguard Russell 2000 Index ETF <0.01% Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
CVNY YieldMax CVNA Option Income Strategy ETF 21M It ranks #67 of 142 in the industry
Based on market cap of $363M.
FAQ
What kind of company is CV?
CV belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of CV?
The market cap of CV is approximately $363M, ranking 3,428 within its sector.
What is the 52-week high and low for CV?
CV has recorded a 52-week high of $15.37 and a low of $4.50.
